The role of histone deacetylase 3 in breast cancer.

Rezgar Rahbari, Yousef Rasmi, Mohammad Hassan Khadem-Ansari, Mohammad Abdi

Medical oncology (Northwood, London, England) 2022 May 17

filter terms:

It has been recently revealed that Histone Deacetylase (HDAC) 3, a unique member of the HDACs family, can trigger and progress cancers by alternation in genes expression and proteins activity. Epigenetic modifications by HDACs have been studied well in various cancer cells. Recent studies have focused on the HDAC enzymes as a possible target in cancer therapy. There are significant documents on upregulation of HDAC3 in breast cancer (BC) cells which suggest an oncogenic role for this enzyme. Interestingly, some studies showed that HDAC3 inhibition could be considered as a promising target in breast cancer therapy, and thus far, several inhibitors from different nature have been introduced. In this review, we discussed the function and highlight the existing inhibitors of HDAC3 in BC pathogenesis and therapy. © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Citation

Rezgar Rahbari, Yousef Rasmi, Mohammad Hassan Khadem-Ansari, Mohammad Abdi. The role of histone deacetylase 3 in breast cancer. Medical oncology (Northwood, London, England). 2022 May 17;39(5):84